Need help finding what you are looking for?
Contact Us
PUBLISHER: BCC Research | PRODUCT CODE: 1940468
PUBLISHER: BCC Research | PRODUCT CODE: 1940468
Radioligand Therapeutics in Cancer Treatment: Global Markets
PUBLISHED:
PAGES: 106 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
The global market for radioligand therapeutics in cancer treatment is estimated to grow from $2.6 billion in 2025 to $4.8 billion by the end of 2030, at a compound annual growth rate (CAGR) of 13.1% from 2025 through 2030.
The North American market for radioligand therapeutics in cancer treatment is estimated to grow from $2.1 billion in 2025 to $3.9 billion by the end of 2030, at a CAGR of 13.1% from 2025 through 2030.
The emerging regions’ market for radioligand therapeutics in cancer treatment is estimated to grow from $91.1 million in 2025 to $191.4 million by the end of 2030, at a CAGR of 16% from 2025 through 2030.
Report Scope
This report provides an in-depth analysis of the global market for radioligand therapeutics (RLT) in cancer treatment. It presents detailed market data for 2024 (base year), estimates for 2025 and forecasts with compound annual growth rates (CAGR) through 2030. The study evaluates current market dynamics, emerging trends and future growth potential driven by the adoption of prostate-specific membrane antigen (PSMA)- and somatostatin receptor (SSTR)-targeted therapies.
The report assesses the competitive environment, including product-level analysis of approved radioligand therapies such as 177Lu-vipivotide tetraxetan (Pluvicto) and 177Lu-dotatate (Lutathera), as well as pipeline assets targeting PSMA, SSTR, gastrin-releasing peptide receptor (GRPR) and other tumor-specific receptors. It also examines regulatory pathways and reimbursement frameworks.
Market segmentation encompasses product type, indication type, and end user, with additional assessments of drivers, restraints, opportunities, technological advances, and strategic activities such as collaborations, acquisitions, clinical trial investments, and expansion of isotope production capacity.
Segmental-level market data (by product type, indication type and end user) is limited to the North America region. This limitation highlights that the market for radioligand therapeutics in cancer treatment is centered in the U.S., where a single company's products (Pluvicto and Lutathera from Novartis AG) account for the majority of global sales and where reliable, detailed data are accessible. In other regions, RLT is still in an early stage, with limited commercial adoption and insufficient transparent data to enable detailed segment-level analysis.
Report Includes
- 15 data tables and 57 additional tables
- Overview and an analysis of the global markets for radioligand therapeutics (RLT) in cancer treatment
- Analyses of the global market trends, with historic revenue (sales data) from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
- Estimates of the current market size and revenue prospects for the global market, along with a corresponding market share analysis based on product type, disease indication, end user and region
- Facts and figures about market dynamics, opportunities and deterrents, technological advances, regulations, prospects and the impact of macroeconomic variables
- Highlights of promising new advancements in precision oncology, the emergence of innovative and effective theranostic agents, applications and potential
- Insights derived from Porter's Five Forces model, as well as global supply chain analyses
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
- A relevant patent analysis, featuring key granted and published patents
- Analysis of the industry structure, including companies' market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook
- Profiles of the leading companies, including Novartis AG, ITM Isotope Technologies Munich SE, Telix Pharmaceuticals Ltd., RayzeBio Inc., and Lilly USA LLC.
Product Code: PHM288A
Table of Contents
Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
- Current Market Scenario
- Market Dynamics and Growth Factors
- Emerging Technologies
- Segmental Analysis
- Regional Analysis
- Conclusion
Chapter 2 Market Overview
- Overview
- Macroeconomic Factors Analysis
- Geographical Factor
- Healthcare Spend
- Cancer Burden and Demographics
- Reimbursement and Funding Climate
- Impact of U.S. Tariffs on Radioligand Therapeutics in Cancer Treatment Supply Chains
- Porter's Five Forces Analysis
- Bargaining Power of Buyers
- Bargaining Power of Suppliers
- Potential for New Entrants
- Threat of Substitutes
- Competitiveness in the Industry
Chapter 3 Market Dynamics
- Market Dynamics
- Market Drivers
- Rising Cancer Incidence and Population Aging
- Increasing Approvals and Label Expansions of Radioligand Therapeutics Products
- Centers for Medicare and Medicaid Services (CMS) Separate Payment for Therapeutic Radiopharmaceuticals
- Market Restraints/Challenges
- Therapeutic Isotope Supply Constraints
- Nuclear Medicine and Radiopharmacy Workforce Shortage
- Growing Competition from Alternative Modalities such as Antibody-Drug Conjugates (ADCs)
- Market Opportunities
- Development of Alpha-Emitter Therapies and Novel Targets
- Earlier-Line Use and Combination Regimens with Standard of Care
- Increasing R&D Investments and Strategic Alliances
Chapter 4 Regulatory Landscape
- Overview
- Regulatory Frameworks by Country/Region
- U.S.
- Canada
- Europe
- Emerging Markets
Chapter 5 Emerging Technologies and Developments
- Key Takeaways
- Targeted Alpha Therapies (TATs)
- Next-Generation Isotopes and Smarter Ligands
- Personalized, Dosimetry-Guided RLT (AI-Assisted)
Chapter 6 Pipeline and Clinical Analysis
- Key Takeaways
- Pipeline Analysis
- Clinical Trials Analysis
- Key Takeaways
- Clinical Trial Studies on Radioligand Therapeutics in Cancer Treatment
Chapter 7 Patent Analysis
- Key Takeaways
- Patent Analysis
- Recent Patent Grants
Chapter 8 Market Segmentation Analysis
- Segmentation Breakdown
- Global Market for Radioligand Therapeutics in Cancer Treatment, by Product Type
- Key Takeaways
- Lutetium-177 Dotatate
- Others (Pipeline)
- Global Market for Radioligand Therapeutics in Cancer Treatment, by Indication
- Key Takeaways
- Prostate Cancer
- Neuroendocrine Tumors
- Others (Pipeline)
- Global Market for Radioligand Therapeutics in Cancer Treatment, by End User
- Key Takeaways
- Academic/Comprehensive Cancer Centers
- Hospital-Based Nuclear Medicine
- Specialized Private Nuclear Medicine Clinics
- Geographic Breakdown
- Global Market for Radioligand Therapeutics in Cancer Treatment, by Region
- Key Takeaways
- North America
- Europe
- Emerging Markets
Chapter 9 Competitive Intelligence
- Competitive Landscape
- Key Takeaways
- Novartis AG RLT Sales, 2024
- Other Competitors in the Pipeline
Chapter 10 Sustainability in the Global Market for Radioligand Therapeutics in Cancer Treatment: An ESG Perspective
- Introduction to ESG
- Sustainability in the Global Market for Radioligand Therapeutics in Cancer Treatment
- ESG Perspective
- Environmental Impact
- Social Impact
- Governance Impact
- ESG Risk Ratings
- Conclusion
Chapter 11 Appendix
- Methodology
- Abbreviations
- Sources
- Company Profiles
- ABDERA THERAPEUTICS
- ARICEUM THERAPEUTICS
- CLARITY PHARMACEUTICALS
- CONVERGENT THERAPEUTICS INC.
- CURIUM
- FUSION PHARMA
- ITM ISOTOPE TECHNOLOGIES MUNICH SE
- LILLY USA LLC.
- NOVARTIS AG
- ORANO MED
- PERSPECTIVE THERAPEUTICS
- PRECIRIX
- RADIOPHARM THERANOSTICS LTD.
- RAYZEBIO INC.
- TELIX PHARMACEUTICALS LTD.
- Few Emerging Companies in the Global Market for Radioligand Therapeutics in Cancer Treatment
Product Code: PHM288A
List of Tables
- Summary Table : Global Market for Radioligand Therapeutics in Cancer Treatment, by Region, Through 2030
- Table 1 : Clinical-Commercial Heatmap, by Target and Indication, 2025-2030 Outlook
- Table 2 : Healthcare Spending Snapshot and Implications for Radioligand Therapeutics Rollout (Developed versus Emerging Markets)
- Table 3 : Reimbursement and Funding Climate, 2024 and 2025
- Table 4 : Recent U.S. Regulatory Actions Affecting Radioligand Therapeutics
- Table 5 : Selected Clinical Trials Studies on Radioligand Therapeutics in Cancer Treatment
- Table 6 : Recent Patents in Radioligand Therapeutics in Cancer Treatment, 2024 and 2025
- Table 7 : Global Market for Radioligand Therapeutics in Cancer Treatment, by Product Type, 2022-2024
- Table 8 : Global Market for Radioligand Therapeutics in Cancer Treatment, by Indication, 2022-2024
- Table 9 : Global Market for Radioligand Therapeutics in Cancer Treatment, by End User, Through 2030
- Table 10 : Global Market for Radioligand Therapeutics in Cancer Treatment, by Region, Through 2030
- Table 11 : North American Market for Radioligand Therapeutics in Cancer Treatment, by Product Type, Through 2030
- Table 12 : North American Market for Radioligand Therapeutics in Cancer Treatment, by Indication, Through 2030
- Table 13 : North American Market for Radioligand Therapeutics in Cancer Treatment, by End User, Through 2030
- Table 14 : North American Market for Radioligand Therapeutics in Cancer Treatment, by Country, Through 2030
- Table 15 : European Market for Radioligand Therapeutics in Cancer Treatment, Through 2030
- Table 16 : Emerging Regions' Market for Radioligand Therapeutics in Cancer Treatment, Through 2030
- Table 17 : Strategic Initiatives in the Global Market for Radioligand Therapeutics in Cancer Treatment, 2025
- Table 18 : Key Focus Areas in ESG Metrics
- Table 19 : ESG Rankings for Leading Companies in the Global Market for Radioligand Therapeutics in Cancer Treatment, 2025*
- Table 20 : Abbreviations Used in this Report
- Table 21 : Report Sources
- Table 22 : Abdera Therapeutics: Company Snapshot
- Table 23 : Abdera Therapeutics: Product Pipeline
- Table 24 : Abdera Therapeutics: News/Key Developments, 2023 and 2024
- Table 25 : Ariceum Therapeutics: Company Snapshot
- Table 26 : Ariceum Therapeutics: Product Pipeline
- Table 27 : Ariceum Therapeutics: News/Key Developments, 2022-2025
- Table 28 : Clarity Pharmaceuticals: Company Snapshot
- Table 29 : Clarity Pharmaceuticals: Product Pipeline
- Table 30 : Clarity Pharmaceuticals: News/Key Developments, 2024 and 2025
- Table 31 : Convergent Therapeutics Inc.: Company Snapshot
- Table 32 : Convergent Therapeutics Inc.: Product Pipeline
- Table 33 : Convergent Therapeutics Inc.: News/Key Developments, 2022-2025
- Table 34 : Curium: Company Snapshot
- Table 35 : Curium: Product Pipeline
- Table 36 : Curium: News/Key Developments, 2024
- Table 37 : Fusion Pharma: Company Snapshot
- Table 38 : Fusion Pharma: Product Pipeline
- Table 39 : Fusion Pharma: News/Key Developments, 2024
- Table 40 : ITM Isotope Technologies Munich SE: Company Snapshot
- Table 41 : ITM Isotope Technologies Munich SE: Product Pipeline
- Table 42 : ITM Isotope Technologies Munich SE: News/Key Developments, 2024 and 2025
- Table 43 : Lilly USA LLC.: Company Snapshot
- Table 44 : Lilly USA LLC.: Financial Performance, FY 2023 and 2024
- Table 45 : Lilly USA LLC.: Product Pipeline
- Table 46 : Lilly USA LLC.: News/Key Developments, 2023-2025
- Table 47 : Novartis AG: Company Snapshot
- Table 48 : Novartis AG: Financial Performance, FY 2023 and 2024
- Table 49 : Novartis AG: Product Portfolio
- Table 50 : Novartis AG: News/Key Developments, 2023-2024
- Table 51 : Orano Med: Company Snapshot
- Table 52 : Orano Med: Product Pipeline
- Table 53 : Orano Med: News/Key Developments, 2023-2025
- Table 54 : Perspective Therapeutics: Company Snapshot
- Table 55 : Perspective Therapeutics: Financial Performance, FY 2023 and 2024
- Table 56 : Perspective Therapeutics: Product Pipeline
- Table 57 : Perspective Therapeutics: News/Key Developments, 2023 and 2024
- Table 58 : Precirix: Company Snapshot
- Table 59 : Precirix: Product Pipeline
- Table 60 : Precirix: News/Key Developments, 2025
- Table 61 : Radiopharm Theranostics Ltd.: Company Snapshot
- Table 62 : Radiopharm Theranostics Ltd.: Product Pipeline
- Table 63 : Radiopharm Theranostics Ltd.: News/Key Developments, 2024 and 2025
- Table 64 : RayzeBio Inc.: Company Snapshot
- Table 65 : RayzeBio Inc.: Product Pipeline
- Table 66 : RayzeBio Inc.: News/Key Developments, 2024
- Table 67 : Telix Pharmaceuticals Ltd.: Company Snapshot
- Table 68 : Telix Pharmaceuticals Ltd.: Financial Performance, FY 2023 and 2024
- Table 69 : Telix Pharmaceuticals Ltd.: Product Pipeline
- Table 70 : Telix Pharmaceuticals Ltd.: News/Key Developments, 2024 and 2025
- Table 71 : Few Emerging Companies in the Global Market for Radioligand Therapeutics in Cancer Treatment
List of Figures
- Summary Figure : Global Market Shares for Radioligand Therapeutics in Cancer Treatment, by Region, 2024
- Figure 1 : Global RLT Relevant Cancer Burden Versus Ageing Trend, 2022
- Figure 2 : Porter's Five Forces Analysis of the Global Market for Radioligand Therapeutics in Cancer Treatment
- Figure 3 : Market Dynamics of Radioligand Therapeutics in Cancer Treatment
- Figure 4 : Global Market Shares for Radioligand Therapeutics in Cancer Treatment, by Product Type, 2024
- Figure 5 : Global Market Shares for Radioligand Therapeutics in Cancer Treatment, by Indication, 2024
- Figure 6 : Global Market Shares for Radioligand Therapeutics in Cancer Treatment, by End User, 2024
- Figure 7 : Global Market Shares for Radioligand Therapeutics in Cancer Treatment, by Region, 2024
- Figure 8 : North American Market Shares for Radioligand Therapeutics in Cancer Treatment, by Product Type, 2024
- Figure 9 : North American Market Shares for Radioligand Therapeutics in Cancer Treatment, by Indication, 2024
- Figure 10 : North American Market Shares for Radioligand Therapeutics in Cancer Treatment, by End User, 2024
- Figure 11 : North American Market Shares for Radioligand Therapeutics in Cancer Treatment, by Country, 2024
- Figure 12 : Advantages of ESG for Companies
- Figure 13 : Lilly USA LLC.: Revenue Share, by Country/Region, FY 2024
- Figure 14 : Novartis AG: Revenue Share, by Business Unit, FY 2024
- Figure 15 : Novartis AG: Revenue Share, by Country/Region, FY 2024
- Figure 16 : Telix Pharmaceuticals Ltd.: Revenue Share, by Business Unit, FY 2024
- Figure 17 : Telix Pharmaceuticals Ltd.: Revenue Share, by Country/Region, FY 2024
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.